Bemarituzumab with chemotherapy for previously untreated advanced gastric or gastroesophageal junction cancer

Bemarituzumab in combination with chemotherapy is in clinical development for the treatment of previously untreated locally advanced, or metastatic gastric or gastroesophageal junction (GEJ) cancer. Gastric (or stomach) cancer is when abnormal cells in the stomach start to grow and divide in an uncontrolled way. GEJ cancer starts in the junction where the food pipe joins the stomach. Locally advanced means that cancer has grown outside the body part where it started but has not yet spread to other parts of the body; metastatic cancer is cancer that has spread from the place it first formed to another part of the body. Gastric cancer, including GEJ cancer, is often diagnosed at an advanced stage and is therefore associated with poor outcomes. There remains an unmet need for new and effective treatment options that target the proteins that are expressed in these cancers to improve health outcomes.